Cited 0 times in
A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김성희 | - |
dc.contributor.author | 남기택 | - |
dc.contributor.author | 박인호 | - |
dc.contributor.author | 서준영 | - |
dc.contributor.author | 신전수 | - |
dc.date.accessioned | 2024-01-03T00:16:20Z | - |
dc.date.available | 2024-01-03T00:16:20Z | - |
dc.date.issued | 2023-12 | - |
dc.identifier.issn | 0166-3542 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197210 | - |
dc.description.abstract | Coronavirus Disease 2019 (COVID-19) pandemic is severely impacting the world, and tremendous efforts have been made to deal with it. Despite many advances in vaccines and therapeutics, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants remains an intractable challenge. We present a bivalent Receptor Binding Domain (RBD)-specific synthetic antibody, specific for the RBD of wild-type (lineage A), developed from a non-antibody protein scaffold composed of LRR (Leucine-rich repeat) modules through phage display. We further reinforced the unique feature of the synthetic antibody by constructing a tandem dimeric form. The resulting bivalent form showed a broader neutralizing activity against the variants. The in vivo neutralizing efficacy of the bivalent synthetic antibody was confirmed using a human ACE2-expressing mouse model that significantly alleviated viral titer and lung infection. The present approach can be used to develop a synthetic antibody showing a broader neutralizing activity against a multitude of SARS-CoV-2 variants. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | ANTIVIRAL RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antibodies | - |
dc.subject.MESH | Antibodies, Neutralizing / therapeutic use | - |
dc.subject.MESH | Antibodies, Viral / therapeutic use | - |
dc.subject.MESH | COVID-19* | - |
dc.subject.MESH | Cell Surface Display Techniques | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | SARS-CoV-2* / genetics | - |
dc.subject.MESH | Spike Glycoprotein, Coronavirus / genetics | - |
dc.title | A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | BioMedical Science Institute (의생명과학부) | - |
dc.contributor.googleauthor | Dong-Gun Kim | - |
dc.contributor.googleauthor | Uijin Kim | - |
dc.contributor.googleauthor | In Ho Park | - |
dc.contributor.googleauthor | Bumhan Ryu | - |
dc.contributor.googleauthor | Youngki Yoo | - |
dc.contributor.googleauthor | Jeong Seok Cha | - |
dc.contributor.googleauthor | Ga-Yeon Yoon | - |
dc.contributor.googleauthor | Sung-Hee Kim | - |
dc.contributor.googleauthor | Heeju Oh | - |
dc.contributor.googleauthor | Jun-Young Seo | - |
dc.contributor.googleauthor | Ki Taek Nam | - |
dc.contributor.googleauthor | Je Kyung Seong | - |
dc.contributor.googleauthor | Jeon-Soo Shin | - |
dc.contributor.googleauthor | Hyun-Soo Cho | - |
dc.contributor.googleauthor | Hak-Sung Kim | - |
dc.identifier.doi | 10.1016/j.antiviral.2023.105738 | - |
dc.contributor.localId | A06017 | - |
dc.contributor.localId | A01243 | - |
dc.contributor.localId | A01631 | - |
dc.contributor.localId | A01911 | - |
dc.contributor.localId | A02144 | - |
dc.relation.journalcode | J02902 | - |
dc.identifier.eissn | 1872-9096 | - |
dc.identifier.pmid | 37944822 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0166354223002164 | - |
dc.subject.keyword | Cryo-EM | - |
dc.subject.keyword | Receptor binding domain (RBD) variant | - |
dc.subject.keyword | Repebody | - |
dc.subject.keyword | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | - |
dc.subject.keyword | Synthetic antibody | - |
dc.contributor.alternativeName | Kim, Sung-Hee | - |
dc.contributor.affiliatedAuthor | 김성희 | - |
dc.contributor.affiliatedAuthor | 남기택 | - |
dc.contributor.affiliatedAuthor | 박인호 | - |
dc.contributor.affiliatedAuthor | 서준영 | - |
dc.contributor.affiliatedAuthor | 신전수 | - |
dc.citation.volume | 220 | - |
dc.citation.startPage | 105738 | - |
dc.identifier.bibliographicCitation | ANTIVIRAL RESEARCH, Vol.220 : 105738, 2023-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.